OncoMatch/Clinical Trials/NCT06083207
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma
Is NCT06083207 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies IBI3003 for multiple myeloma.
Treatment: IBI3003 — This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 23\~116 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify